Breakthrough T1D was on site in Chicago, IL from June 20-23 for the American Diabetes Association’s (ADA) 85th Scientific Sessions. We’ve reported on the latest-and-greatest type 1 diabetes (T1D) advancements—including many driven by Breakthrough T1D funding. See below for all our ADA 2025 coverage spanning cures, improving the lives of people with T1D, and clinical adoption of T1D therapies, treatments, and devices.
Improving Lives
Medical Affairs
ADA recap with Aaron Kowalski, Ph.D.
Looking for more ADA news? Tune in below to hear Breakthrough T1D Chief Executive Officer Dr. Aaron Kowalski cover the top advancements presented at ADA 2025.
Thanks for joining us throughout our coverage of the ADA 85th Scientific Sessions. We’ve made incredible progress across all our research priorities areas, including cures therapies, treatments, and devices. Breakthrough T1D staff and leadership were on-site hosting and participating in panel discussions, meeting with industry leaders, and engaging with researchers from around the world to accelerate T1D research progress. Breakthrough T1D-funded research was front-and-center, showcasing the reach of our impact driven by supporters like you. That’s a wrap on ADA 2025—we’re already looking forward to ADA 2026!
